US · 21 CFR
21 CFR Part 212
Current Good Manufacturing Practice for Positron Emission Tomography Drugs
eCFR, up to date as of 2026-11-12
조항 목차
- 212.1What are the meanings of the technical terms used in these regulations?
- 212.2What is current good manufacturing practice for PET drugs?
- 212.5To what drugs do the regulations in this part apply?
- 212.10What personnel and resources must I have?
- 212.20What activities must I perform to ensure drug quality?
- 212.30What requirements must my facilities and equipment meet?
- 212.40How must I control the components I use to produce PET drugs and the containers and closures I package them in?
- 212.50What production and process controls must I have?
- 212.60What requirements apply to the laboratories where I test components, in-process materials, and finished PET drug products?
- 212.61What must I do to ensure the stability of my PET drug products through expiry?
- 212.70What controls and acceptance criteria must I have for my finished PET drug products?
- 212.71What actions must I take if a batch of PET drug product does not conform to specifications?
- 212.80What are the requirements associated with labeling and packaging PET drug products?
- 212.90What actions must I take to control the distribution of PET drug products?
- 212.100What do I do if I receive a complaint about a PET drug product produced at my facility?
- 212.110How must I maintain records of my production of PET drugs?
표지·목차 원문
Authority:21 U.S.C. 321, 351, 352, 355, 371, 374; Sec. 121, Pub. L. 105-115, 111 Stat. 2296.
Source:74 FR 65431, Dec. 10, 2009, unless otherwise noted.
출처: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · 수집일 2026-11-16